Shots:
- EVOQ Therapeutics has entered into a collaboration & license agreement with Sanofi to advance EVOQ’s NanoDisc tech in immunology
- As per the deal, both companies will jointly lead research activities, with Sanofi responsible for global development & commercialization efforts. In exchange, EVOQ will receive over $500M, incl. upfront, preclinical, development & sales milestones, with tiered royalties
- NanoDisc platform utilizes synthetic HDL NanoDisc to deliver antigens & small molecules for restoring immune tolerance in pts with autoimmune disorders like celiac disease, type 1 diabetes, MOGAD antibody disease, rheumatoid arthritis, & lupus
Ref: EVOQ Therapeutics | Image: EVOQ Therapeutics and Sanofi| Press Release
Related News:- Novo Nordisk Enters ~$2.1B Deal with Omeros to Advance Zaltenibart for Rare Blood & Kidney Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
